TY - JOUR A1 - Singh, Amit K. A1 - Kingston, Joseph J. A1 - Gupta, Shishir K. A1 - Batra, Harsh V. T1 - Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection JF - Frontiers in Microbiology N2 - Studies investigating the correlates of immune protection against Yersinia infection have established that both humoral and cell mediated immune responses are required for the comprehensive protection. In our previous study, we established that the bivalent fusion protein (rVE) comprising immunologically active regions of Y pestis LcrV (100-270 aa) and YopE (50-213 aa) proteins conferred complete passive and active protection against lethal Y enterocolitica 8081 challenge. In the present study, cohort of BALB/c mice immunized with rVE or its component proteins rV, rE were assessed for cell mediated immune responses and memory immune protection against Y enterocolitica 8081 rVE immunization resulted in extensive proliferation of both CD4 and CD8 T cell subsets; significantly high antibody titer with balanced IgG1: IgG2a/IgG2b isotypes (1:1 ratio) and up regulation of both Th1 (INF-\(\alpha\), IFN-\(\gamma\), IL 2, and IL 12) and Th2 (IL 4) cytokines. On the other hand, rV immunization resulted in Th2 biased IgG response (11:1 ratio) and proliferation of CD4+ T-cell; rE group of mice exhibited considerably lower serum antibody titer with predominant Th1 response (1:3 ratio) and CD8+ T-cell proliferation. Comprehensive protection with superior survival (100%) was observed among rVE immunized mice when compared to the significantly lower survival rates among rE (37.5%) and rV (25%) groups when IP challenged with Y enterocolitica 8081 after 120 days of immunization. Findings in this and our earlier studies define the bivalent fusion protein rVE as a potent candidate vaccine molecule with the capability to concurrently stimulate humoral and cell mediated immune responses and a proof of concept for developing efficient subunit vaccines against Gram negative facultative intracellular bacterial pathogens. KW - I-tasser KW - Yersinia enterocolitica KW - memory immune responses KW - cytokine profiling KW - CD8+T cells KW - CD4+T cells KW - recombinant protein rVE KW - resistance KW - pneumonic plague KW - pestis infection KW - nonhuman-primates KW - III secretion KW - V-antigen KW - mice KW - vaccine Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136114 VL - 6 IS - 1407 ER - TY - JOUR A1 - Sauerbrei, A. A1 - Langenhan, T. A1 - Brandstädt, A. A1 - Schmidt-Ott, R. A1 - Krumbholz, A. A1 - Girschick, H. A1 - Huppertz, H. A1 - Kaiser, P. A1 - Liese, J. A1 - Streng, A. A1 - Niehues, T. A1 - Peters, J. A1 - Sauerbrey, A. A1 - Schroten, H. A1 - Tenenbaum, T. A1 - Wirth, S. A1 - Wutzler, P. T1 - Prevalence of antibodies against influenza A and B viruses in children in Germany, 2008 to 2010 JF - Eurosurveillance N2 - The prevalence of influenza A and B virus-specific IgG was determined in sera taken between 2008 and 2010 from 1,665 children aged 0-17 years and 400 blood donors in Germany. ELISA on the basis of whole virus antigens was applied. Nearly all children aged nine years and older had antibodies against influenza A. In contrast, 40% of children aged 0-4 years did not have any influenza A virus-specific IgG antibodies. Eighty-six percent of 0-6 year-olds, 47% of 7-12 year-olds and 20% of 13-17 year-olds were serologically naive to influenza B viruses. By the age of 18 years, influenza B seroprevalence reached approximately 90%. There were obvious regional differences in the seroprevalence of influenza B in Germany. In conclusion, seroprevalences of influenza A and influenza B increase gradually during childhood. The majority of children older than eight years have basal immunity to influenza A, while comparable immunity against influenza B is only acquired at the age of 18 years. Children aged 0-6 years, showing an overall seroprevalence of 67% for influenza A and of 14% for influenza B, are especially at risk for primary infections during influenza B seasons. KW - disease KW - healthy children KW - vaccine KW - burden KW - hospitalizations KW - efficacy Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117347 SN - 1560-7917 VL - 19 IS - 5 ER - TY - JOUR A1 - Roier, Sandro A1 - Leitner, Deborah R. A1 - Iwashkiw, Jeremy A1 - Schild-Prüfert, Kristina A1 - Feldman, Mario F. A1 - Krohne, Georg A1 - Reidl, Joachim A1 - Schild, Stefan T1 - Intranasal Immunization with Nontypeable Haemophilus influenzae Outer Membrane Vesicles Induces Cross-Protective Immunity in Mice JF - PLoS One N2 - Haemophilus influenzae is a Gram-negative human-restricted bacterium that can act as a commensal and a pathogen of the respiratory tract. Especially nontypeable H. influenzae (NTHi) is a major threat to public health and is responsible for several infectious diseases in humans, such as pneumonia, sinusitis, and otitis media. Additionally, NTHi strains are highly associated with exacerbations in patients suffering from chronic obstructive pulmonary disease. Currently, there is no licensed vaccine against NTHi commercially available. Thus, this study investigated the utilization of outer membrane vesicles (OMVs) as a potential vaccine candidate against NTHi infections. We analyzed the immunogenic and protective properties of OMVs derived from various NTHi strains by means of nasopharyngeal immunization and colonization studies with BALB/c mice. The results presented herein demonstrate that an intranasal immunization with NTHi OMVs results in a robust and complex humoral and mucosal immune response. Immunoprecipitation revealed the most important immunogenic proteins, such as the heme utilization protein, protective surface antigen D15, heme binding protein A, and the outer membrane proteins P1, P2, P5 and P6. The induced immune response conferred not only protection against colonization with a homologous NTHi strain, which served as an OMV donor for the immunization mixtures, but also against a heterologous NTHi strain, whose OMVs were not part of the immunization mixtures. These findings indicate that OMVs derived from NTHi strains have a high potential to act as a vaccine against NTHi infections. KW - conjugate KW - obstructive pulmonary disease KW - vaccine KW - vibrio cholerae KW - detoxified lipooligosaccharide KW - nasopharyngeal colonization KW - functional characterization KW - growing escherichia coli KW - DNA-binding vesicles KW - otitis media KW - hemophilus influenzae Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135201 VL - 7 IS - 8 ER - TY - THES A1 - Racek, Tomáš T1 - Entwicklung und Erprobung eines Impfkonstrukts für das Humane Immundefektvirus (HIV) auf der Basis eines replikationsinkompetenten HIV-Vektors T1 - Development and testing of HIV-1 vaccine based on replication-incompetent HIV vector N2 - Immunogenität von retroviralen und lentiviralen Vektoren wurde als ein Haupthindernis für deren Applikation in der Gentherapie betrachtet worden. Dies kann jedoch als Vorteil für den Einsatz dieser Vektoren als Impfstoffkandidaten gegen HIV-Infektion und AIDS genutzt werden. Um das Potenzial von lentiviralen Vektoren eine humorale und zelluläre Immunantwort zu induzieren zu prüfen, wurde eine Reihe VSV-G-pseudotypisierter replikations-inkompetenter HIV-1-Vektoren hergestellt, die entweder ein Kodon-optimiertes HIV-p17/p24 (hgag)- oder das Grün fluoreszierende Protein (GFP)-Transgen enthalten. Die Infektion mit dem VSV-G pseudotypisierten HIV-1-Vektor pGJ2 führte in allen getesteten Zelllinien und auch in primären humanen und murinen Zellen zur Transgenexpression. Ebenfalls konnte eine direkte Expression des Transgens in vivo nachgewiesen werden. Balb/c-Mäuse wurden in einem Vektoren- oder DNA-Prime und Vektoren-Boost-Verfahren immunisiert und die humorale und zelluläre Immunantwort wurde untersucht. Die Primärimmunisierung mit DNA und Boosting mit den lentiviralen Vektoren induzierte eine Gag-spezifische humorale Immunantwort, hohe Titer von VSV-G-neutralisierenden Antikörpern und eine Gag- und EGFP-spezifische zytotoxische T-Zell-Antwort. Dabei wurde festgestellt, dass sowohl Strukturbestandteile des lentiviralen Vektors als auch die Transgenexpression zur Aktivierung der Immunantwort beitrugen. So machen die einzigartigen biologischen und immunologischen Eigenschaften der replikationsdefizienten HIV-Vektoren aus diesen Konstrukten wertvolle Werkzeuge, um weiter die Immunmechanismen, die für den Schutz gegen HIV-Infektion und Krankheit bedeutsam sind, zu studieren. Im Rahmen der hierzu durchgeführten Arbeiten wurden außerdem Vacciniavirus/HIV-1-Hybridvektoren hergestellt und analysiert. Um die Transkription der lentiviralen Vektor-Kassette durch das Vacciniavirus zu ermöglichen, wurde vor den Transkriptionsstart ein Vaccinia-Promotor gesetzt und an das 3’-Ende das Transkription-Stoppsignal angehängt. Obwohl die genomische Analyse eine erfolgreiche Herstellung der Hybridvektoren bestätigen konnte, muss die Produktion der lentiviralen Vektoren nach der Vaccinia-Infektion weiter optimiert werden. Nichtsdestotrotz könnte die Kombination von replizierenden Vacciniaviren und replikationsinkompetenten HIV-Vektoren ein neuartiges Impfkonzept darstellen. Die Expression von HIV-Strukturgenen würde in der ersten Phase der Infektion mit dem Vacciniavirus/HIV-1-Hybridvektor zu einer starken humoralen und zellulären Immunantwort führen. Die Bildung von lentiviralen Vektoren würde diese Immunantwort weiter boosten, und falls die lentivirale Vektorkassette dann ein entsprechendes Transgen enthalten würde, würde dies weiter die Immunantwort verstärken und vor allem könnte diese Art des Impfstoffes eine langzeitige falls nicht dauerhafte HIV-spezifische Immunantwort erzeugen. N2 - Immunogenicity of retroviral and lentiviral vectors has been regarded as a major impediment to the use of these constructs in gene therapy. However, this may be exploited for the design of vaccine candidates against HIV infection and AIDS. To test the specific potential to induce antibody and cytotoxic T lymphocyte responses to HIV-derived vectors, a set of VSV-G-pseudotyped replication-defective vectors that contain a codon-optimized p17/p24 HIV-1 Gag or the green fluorescent protein (GFP) gene as transgene were constructed. Infection with the gag or gfp gene-containing vector particles resulted in transgene expression in cell lines and primary human and murine cells. Moreover, the direct transgene expression mediated by this lentiviral vector was also detected after in vivo application. Balb/c mice were immunised in a vector or DNA prime vector boost fashion and humoral and cellular immune responses were examined. Immunisation with DNA as prime, and the lentiviral vectors as boost, induced a Gag-specific antibody response, high titers of neutralising antibodies directed against the VSV-G protein and Gag- and EGFP-specific cytotoxic T lymphocyte (CTL) responses. CTL responses were induced by both structural proteins contained in the vector preparation and through expression of the transgene. Thus, the unique biological and immunologic properties of single-cycle HIV vectors make the constructs valuable tools to further study immune mechanisms relevant to protection from HIV infection and disease. Moreover, to develop a novel HIV vaccine strategy, recombinant vaccinia viruses that express functional HIV-based vector genomes, were constructed. For this purpose, the proviral lentiviral genome, engineered into the vaccinia virus, was subjected to several modifications, including the replacement of retroviral promoter sequences by vaccinia virus sequences and the precise fusion of the transcription stop signal downstream of the transcription unit, allowing cytoplasmic transcription of distinct full-length lentiviral transcripts. The developed chimeric vector should be able to produce the transduction-competent lentiviral particels after single infection of the host cells. However, the genome analysis confirm the successful construction of vaccinia/HIV hybrid vector, the generation of lentiviral particles after vaccinia infection have to be optimized. Nevertheless, due to the favorable properties of vaccinia vectors, including high coding capacity, stability, and wide host range, vaccinia viral/HIV chimeric vectors can be promising HIV vaccine candidate. The expression of HIV-structural genes would lead in the first phase of the infection with the vaccinia/HIV-1 hybrid vector to strong humoral and cellular immunity. The generation of lentiviral vectors would boost this immune response, especially if the lentiviral vector cassette will contain an appropriate transgene. This kind of the vaccine could induce strong long-term or lasting HIV-specific immune response. KW - HIV KW - Impfstoff KW - Vektor KW - HIV-1 KW - Vakzine KW - HIV-Vektor KW - Pseudovirion KW - HIV-1 KW - vaccine KW - HIV-vector KW - pseudovirion Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-22014 ER - TY - THES A1 - Pilgrim, Sabine T1 - Entwicklung eines "DNA-Delivery"-Systems auf der Basis von Virulenz-attenuierten Listerien T1 - Development of a DNA delivery system using virulence-attenuated Listeria strains N2 - Virulenz-attenuierte Bakterien sind geeignete Vektoren für den Transport von Vakzine-DNA in das Zytosol von Antigen-präsentierenden Zellen ("DNA delivery"). In dieser Arbeit wurde dazu das intrazelluläre Bakterium Listeria monocytogenes verwendet, welches sich im Zytosol von Zellen vermehrt und fortbewegt. Ausgestattet mit einer intrazellulären Lysis-Kassette kann Listeria in vitro effektiv Plasmid-DNA in das Zytosol verschiedener Zelltypen freisetzen. Zur Virulenz-Attenuierung wurde das Gen iap im Chromosom des Bakteriums deletiert. Der daraus resultierte Stamm, in Folgenden als iap bezeichnet, erwies sich als hoch attenuiert im Modell der murinen Listeriose. Diese Attenuation konnte auf einen Defekt in der Beweglichkeit der Bakterien innerhalb von Wirtszellen zurückgeführt werden, da sich bei diesem Stamm das Protein ActA, das essentiell für die Aktin-basierte Motilität von L. monocytogenes ist, fehlerhaft auf der Oberfläche der Bakterien anordnet. Zusätzlich konnte demonstriert werden, dass iap in der Zellteilung beeinträchtigt ist und deshalb eine veränderte Morphologie aufweist. Im Rahmen dieser Arbeit wurde ein so genanntes "Balanced-lethal" System etabliert. Dazu wurde das essentielle Gens trpS im Chromosom deletiert, während gleichzeitig eine trpS-Expressions-Kassette auf einem Vakzine-Plasmid inseriert wurde. Dieses System gewährleistet, dass das Trägerbakterium dieses Plasmid weder in vitro noch in vivo verliert. Dies ist besonders wichtig im Hinblick auf eine bakteriolytische Lysis-Kassette, welche ebenfalls auf diesem Plasmid kodiert ist. Es wurden verschiedene Lysis-Kassetten, die alle aus einem Listeria-spezifischen Phagenlysin und einem vorangestellten zytosolischen listeriellen Promotor zusammengesetzt waren, miteinander verglichen. Dabei wurde beobachtet, dass die für die Übertragung von Plasmid-DNA in das Zytosol von Wirtszellen wirksamste Phagenlysin-Kassette (PactA-ply118) die Bakterien in vitro nur partial abtötet, während sie in vivo zu einer besonders hohen Attenuation der Bakterien führt. Unter Verwendung dieses "DNA delivery" Systems wurden Mäuse oral mit Listerien infiziert, die ein DNA-Vakzine-Plasmid zur Expression des Leishmania Antigens KMP-11 trugen. Dabei konnte bei 27 % aller Tiere, die zweimal mit diesen Listerien infiziert worden sind, eine KMP-11 spezifische, proliferative Immunantwort gemessen werden. Listerien, die einen Defekt in ihrer Motilität besitzen (delta-iap, delta-actA), erwiesen sich darin beeinträchtigt, Plasmid-DNA im Zytosol von Zellen freizusetzen. Anhand dieser Stämme konnte gezeigt werden, dass die Fähigkeit von L. monocytogenes, sich innerhalb von Zellen zu bewegen und in benachbarte Zellen einzudringen eine wichtige Voraussetzung für einen effizienten Transfer von Plasmid-DNA in vitro darstellt. N2 - Virulence-attenuated bacteria are useful carriers to introduce a DNA vaccine into antigen presenting cells (DNA delivery). To this end, the intracellular bacterium Listeria monocytogenes was used in this work, which is able to replicate and spread inside host cells. Hence Listeriae are able to efficiently release plasmid DNA within the cytosol in vitro when they are provided with a cytosolic lysis cassette. The expression of the antigen by the cell leads to the presentation of antigenic epitopes on the cell's major histocompatibilty complex (MHC) class I molecules, due to the antigen being endogenous. This stimulates the activation of CD8+ T cells which are important for clearance of tumours, parasites and virus infected cells. In order to create a virulence-attenuated carrier strain the gene iap was deleted in the chromosome of the bacterium. The resulting strain, designated as iap, was shown to be highly attenuated in mice. This was due to a defect of the intracellular motility since ActA, a protein which is necessary for actin-based motility of Listeria, was localised incorrectly at the bacterial surface. Additionally, it was demonstrated that iap is impaired in cell division which leads to an altered cell morphology. In this work a so-called balanced-lethal plasmid system was established. The essential gene trpS was deleted from the chromosome of L. monocytogenes and a trpS transcription unit was inserted in a vaccine DNA plasmid thus ensuring that no plasmid loss happens in vitro and also within the host organism. This is in particular important in terms of a bacteriolytic lysis cassette which is also encoded by the plasmid. Different lysis cassettes were tested consisting of a Listeria-specific phage lysin and an intracellular promoter of Listeria. The cassette PactA-ply118 was found the be most effective due to its DNA delivery capacity but it mediates only a partial lysis of the intracellular bacteria. However, this cassette leads to a high attenuation of Listeria in mice. Using this DNA delivery system mice were orally infected with Listeria harbouring a KMP-11 expression plasmid. 27 % of animals infected twice exhibited a specific proliferative response to the leismanial antigen KMP-11. Listeriae with a defect in their spreading capacity (delta-iap, delta-actA) were impaired in the cytosolic release of plasmid DNA. With these strains it was demonstrated, that spreading is an important prerequisite for L. monocytogenes to be an efficient DNA delivery carrier in vitro. KW - Listeria monocytogenes KW - Gentransfer KW - Listeria KW - Gentransfer KW - Vakzinierung KW - p60 KW - "Balanced-lethal" Plasmid-System KW - Listeria KW - DNA delivery KW - vaccine KW - p60 KW - balanced-lethal plasmid system Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-4754 ER - TY - JOUR A1 - Mueller, A. A1 - Stoetter, L. A1 - Kalluvya, S. A1 - Stich, A. A1 - Majinge, C. A1 - Weissbrich, B. A1 - Kasang, C. T1 - Prevalence of hepatitis B virus infection among health care workers in a tertiary hospital in Tanzania JF - BMC Infectious Diseases N2 - Background: Sub-Saharan Africa has a high prevalence of hepatitis B virus (HBV) infections. Health care workers (HCWs) are at high risk of contracting HBV infection through their occupation. Vaccination of HCWs against HBV is standard practice in many countries, but is often not implemented in resource-poor settings. We aimed with this cross-sectional study to determine HBV prevalence, HCW vaccination status, and the risk factors for HCWs contracting HBV infection in Tanzania. Methods: We enrolled 600 HCWs from a tertiary Tanzanian hospital. Their demographics, medical histories, HBV vaccination details and risk factors for contracting blood-borne infections were collected using a standardized questionnaire. Serum samples were tested for HBV and hepatitis C virus (HCV) markers by ELISA techniques, PCR and an anti-HBs rapid test. HCWs were divided in two subgroups: those at risk of contracting HBV (rHCW 79.2 %) via exposure to potentially infectious materials, and those considered not at risk of contracting HBV (nrHCW, 20.8 %). Results: The overall prevalence of chronic HBV infection (HBsAg+, anti-HBc+, anti-HBs-) was 7.0 % (42/598). Chronic HBV infection was found in 7.4 % of rHCW versus 5.6 % of nrHCW(p-value = 0.484). HCWs susceptible to HBV (HBsAg-, anti-HBc-, anti-HBs-) comprised 31.3 %. HBV immunity achieved either by healed HBV infection (HBsAg-, anti-HBc+, anti-HBs+) or by vaccination (HBsAg-, anti-HBc-, anti-HBs+) comprised 36.5 % and 20.2 %, respectively. 4.8 % of participants had indeterminate results (HBsAg-, anti-HBc+, anti-HBc-IgM-, anti-HBs-). Only 77.1 % of HCWs who received a full vaccination course had an anti-HBs titer > 10 ml/U. An anti-HBs point-of-care test was 80.7 % sensitive and 96.9 % specific. There was a significantly higher risk for contracting HBV (anti-HBc+) among those HCW at occupational risk (rHCW) of older age (odds ratios (OR) in rHCW 3.297, p < 0.0001 vs. nrHCW 1.385, p = 0.606) and among those HCW being employed more than 11 years (OR 2.51, p < 0.0001***). HCV prevalence was low (HCV antibodies 1.2 % and HCV-RNA 0.3 %). Conclusions: Chronic HBV infection is common among Tanzanian HCWs. One third of HCWs were susceptible to HBV infection, highlighting the need for vaccination. Due to high prevalence of naturally acquired immunity against HBV pre-testing might be a useful tool to identify susceptible individuals. KW - hepatitis C virus KW - point-of-care test KW - human-immunodeficiency-virus KW - C virus KW - seroprevalence KW - syphilis KW - vaccine KW - Uganda KW - blood KW - hepatitis B virus KW - health care workers KW - Tanzania Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141786 VL - 15 IS - 386 ER - TY - THES A1 - Masic, Anita T1 - Signaling via Interleukin-4 Receptor alpha chain during dendritic cell–mediated vaccination is required to induce protective immunity against Leishmania major in susceptible BALB/c mice T1 - Die auf dendritischen Zellen basierende Immunisierungsstrategie gegen Leishmania major in BALB/c Mäusen ist abhängig von der Stimulation der Interleukin-4 Rezeptor alpha Kette N2 - Cutaneous leishmaniasis is endemic in tropical and subtropical regions of the world. Effective vaccination strategies are urgently needed because of the emergence of drug-resistant parasites and severe side effects of chemotherapy. The research group of Heidrun Moll previously established a DC-based vaccination strategy to induce complete and long-lasting immunity to experimental leishmaniasis using LmAg-loaded and CpG ODN-activated DC as a vaccine carrier. Prevention of tissue damages at the site of L. major inoculation can be achieved if the BALB/c mice were systemically given LmAg-loaded BMDC that had been exposed to CpG ODN. The interest in further exploring the role of IL-4 aroused as previous studies allowed establishing that IL-4 was involved in the redirection of the immune response towards a type 1 profile. Thus, wt BALB/c mice or DC-specific CD11ccreIL-4Rα-/lox BALB/c mice were given either wt or IL-4Rα-deficient LmAg-loaded BMDC exposed or not to CpG ODN prior to inoculation of 2 x 105 stationary phase L. major promastigotes into the BALB/c footpad. The results provide evidence that IL4/IL-4Rα-mediated signaling in the vaccinating DC is required to prevent tissue damages at the site of L. major inoculation, as properly conditioned wt DC but not IL-4Rα-deficient DC were able to confer resistance. Furthermore, uncontrolled L. major population size expansion was observed in the footpad and the footpad draining LN in CD11ccreIL-4Rα-/lox mice immunized with CpG ODN-exposed LmAg-loaded IL-4Rα-deficient DC, indicating the influence of IL-4R-mediated signaling in host DC to control parasite replication. In addition, no footpad damage was observed in BALB/c mice that were systemically immunized with LmAg-loaded wt DC doubly exposed to CpG ODN and recombinant IL-4. Discussing these findings allow the assumption that triggering the IL4/IL4Rα signaling pathway could be a precondition when designing vaccines aimed to prevent damaging processes in tissues hosting intracellular microorganisms. N2 - Die kutane Leishmaniose ist vor allem in den tropischen und subtropischen Regionen endemisch. Die Notwendigkeit der Erforschung und Etablierung einer Impfstoffstrategie basiert auf dem Auftreten von starken Nebenwirkungen während einer medikamentösen Behandlung, als auch auf die Entwicklung von Resistenzen des Parasiten gegenüber herkömmlichen Behandlungsmethoden. Die Arbeitsgruppe um Heidrun Moll etablierte eine auf dendritischen Zellen (DZ) basierende Immunisierungsstrategie, welche langlebige Immunität gegen experimentelle Leishmaniose vermittelt. Dabei dienen CpG ODN-stimulierte DZ als Adjuvans für L.-major–Antigene (LmAg). Die durch Infektion mit Leishmania-Parasiten hervorgerufene Gewebeschädigung kann in BALB/c-Mäusen verhindert werden, vorausgesetzt eine systemische Verabreichung von LmAg-beladenen und CpG ODN-aktivierten DZ erfolgte eine Woche vor der Infektion. Es konnte gezeigt werden, dass der Schutz durch die Induktion einer von Interleukin (IL)-12 und Interferon (IFN)-gamma dominierten T-Helfer (Th)1-Immunantwort herbeigeführt wurde und kranke Kontrollmäuse eine IL-4-dominierte Th2 Immunantwort aufwiesen. Mittlerweile zeigen zahlreiche Studien, dass IL-4 nicht ausschließlich eine krankheitsfördernde Funktion innehat, sondern auch die Fähigkeit zur Einleitung eine Typ-1-Immunantwort besitzt. Auf Grund dieser Studien wurde das Augenmerk auf die Rolle von IL-4 in der DZ-basierten Immunisierung gegen Leishmaniose in BALB/c Mäusen gelegt. In der vorliegenden Arbeit wurde die Notwendigkeit der Stimulation der IL-4 Rezeptor alpha (IL-4Rα) Kette auf DZ, während einer DZ-basierten Immunisierung gegen Leishmaniose in BALB/c Mäusen gezeigt. Um dies zu erreichen, wurden Wildtyp (wt)-BALB/c-Mäuse oder DZ-spezifische CD11ccreIL-4Rα-/lox BALB/c Mäuse entweder mit wt oder IL-4Rα-defizienten LmAg-beladenen DZ mit oder ohne Aktivierung durch CpG ODN, eine Woche vor der Infektion mit 2x105 L. major Promastigoten in den Hinterfuß, immunisiert. Die in dieser Doktorarbeit gezeigten Ergebnisse lassen den Schluss zu, dass die Stimulation der IL-4Rα-Kette auf den als Adjuvans eingesetzten DZ erforderlich ist, um eine Gewebsschädigung an der Infektionsstelle zu verhindern, da konditionierte wt DZ, nicht aber IL-4Rα-defiziente DZ in der Lage sind, Schutz gegen Leishmaniose zu vermitteln. Des Weiteren konnte eine unkontrollierte Ausdehnung von Leishmania-Parasiten im infizierten Fuß und in den angrenzenden Lymphknoten von CD11ccreIL-4Rα-/lox Mäusen beobachtet werden, welche mit CpG ODN-aktivierten und LmAg-beladenen IL-4Rα-defizienten DZ immunisiert wurden. Dieser Befund zeigt den Einfluss der Stimulation der IL-4Rα-Kette auf wirtsansässigen DZ im Hinblick auf die Eindämmung der Parasitenreplikation und Parasitenverbreitung. Zusätzliche Analysen in BALB/c-Mäusen, welche mit LmAg-beladenen, CpG ODN- und rekombinanten IL-4-stimulierten DZ immunisiert wurden, zeigten einen resistenten klinischen Verlauf der Infektion. Die hier gezeigten Ergebnisse lassen die Vermutung zu, dass die durch die IL-4/IL-4Rα-Kette ausgelösten Signale in den DZ eine Grundvoraussetzung für eine erfolgreiche Immunisierung sind und sollten deswegen unbedingt bei der Entwicklung eines Impfstoffes gegen die gewebsschädigenden Folgen einer Leishmaniose oder anderer durch intrazelluläre Mikroorganismen verursachten Infektionen berücksichtigt werden. KW - Leishmania major KW - Dendritische Zelle KW - Immunisierung KW - murine leishmaniasis KW - IL-4 Rezeptor alpha KW - Leishmania major KW - murine leishmaniasis KW - dendritic cells KW - IL-4 KW - IL-4 receptor alpha chain KW - vaccine Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75508 ER - TY - JOUR A1 - Holzmann-Littig, Christopher A1 - Braunisch, Matthias Christoph A1 - Kranke, Peter A1 - Popp, Maria A1 - Seeber, Christian A1 - Fichtner, Falk A1 - Littig, Bianca A1 - Carbajo-Lozoya, Javier A1 - Allwang, Christine A1 - Frank, Tamara A1 - Meerpohl, Joerg Johannes A1 - Haller, Bernhard A1 - Schmaderer, Christoph T1 - COVID-19 vaccination acceptance and hesitancy among healthcare workers in germany JF - Vaccines N2 - Vaccination hesitancy is a threat to herd immunity. Healthcare workers (HCWs) play a key role in promoting Coronavirus disease 2019 (COVID-19) vaccination in the general population. We therefore aimed to provide data on COVID-19 vaccination acceptance/hesitancy among German HCWs. For this exploratory, cross-sectional study, an online survey was conducted in February 2021. The survey included 54 items on demographics; previous vaccination behavior; trust in vaccines, physicians, the pharmaceutical industry and health politics; fear of adverse effects; assumptions regarding the consequences of COVID-19; knowledge about vaccines; and information seeking behavior. Odds ratios with 95% confidence intervals were calculated and chi-square tests were performed. Four thousand five hundred surveys were analyzed. The overall vaccination acceptance was 91.7%. The age group ≤20 years showed the lowest vaccination acceptance. Factors associated with vaccination hesitancy were lack of trust in authorities and pharmaceutical companies. Attitudes among acquaintances were associated with vaccination hesitancy too. Participants with vaccination hesitancy more often obtained information about COVID-19 vaccines via messenger services or online video platforms and underperformed in the knowledge test. We found high acceptance amongst German HCWs. Several factors associated with vaccination hesitancy were identified which could be targeted in HCW vaccination campaigns. KW - COVID-19 KW - vaccine KW - vaccination KW - vaccination hesitancy KW - vaccine refusal KW - vaccination campaign Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242627 SN - 2076-393X VL - 9 IS - 7 ER - TY - THES A1 - Gesser, Martin Benedikt Ambros T1 - Optimierung eines Balanced Lethal Systems für Salmonella Typhi Ty21a T1 - Optimisation of a balanced lethal system in Salmonella Typhi Ty21a N2 - Das Projekt „Balanced Lethal System in Salmonella typhi Ty21a“ der AG Bakterielle Tumortherapie des MSZ zielt auf die Entwicklung eines Vakzinstammes, der in der humanen Krebstherapie zum Einsatz kommen soll. Ziel dieser Arbeit war das zuvor etablierte Balanced Lethal System in Salmonella typhi Ty21a zu optimieren. N2 - The aim of this project is to develop a bacterial vaccine that will be used in cancer immunotherapy. The aim of this dissertation was to improve the established balanced lethal system in Salmonella typhi Ty21a. KW - Immuntherapie KW - Balanced Lethal System KW - Salmonella typhi KW - Vakzinierung KW - Prostatakarzinom KW - Immuntherapie KW - Balanced Lethal System KW - Salmonella typhi KW - Vakzinierung KW - Prostatakarzinom KW - Immunotherapy KW - balanced lethal system KW - salmonella typhi KW - vaccine KW - prostate cancer Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-55740 ER -